Eli Lilly’s Weight-Loss Pill Cuts Sleep Apnoea Episodes by Up to 44% in Late-Stage Trial
Eli Lilly’s once-daily weight-loss pill Foundayo significantly reduced breathing interruptions in adults with obesity and moderate-to-severe sleep apnoea, meeting the main goal of a late-stage trial programme. The company plans to seek US approval for the new use by the end of the year.